Related Experiment Video
Updated: Jun 7, 2026
High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
Published on: June 10, 2025
Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation
Qingyan Zhang1,2,3,4, Chunhui Yuan1,2,3,4, Lin Zhu1,2,3,4
1The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Abstract:
Melanoma, a malignant tumor originating from melanocytes, accounts for only 4% of all skin cancers but is responsible for 75% of skin cancer-related deaths. In recent years, its incidence has steadily increased. Targeted therapies and immunotherapies have made significant strides, emerging as the most effective treatments for metastatic melanoma. Immune checkpoint blockades (ICBs) have become a central component of systemic therapy for advanced melanoma. However, their clinical use is limited by immune-related toxicities, primary and acquired resistance, and marked inter-patient heterogeneity in response. As a result, personalized treatment approaches are urgently needed. This paper provides a comprehensive review of recent advancements in melanoma immunotherapy, synthesizing findings from existing research and clinical trials. It highlights the progress made in understanding various immune checkpoints in melanoma and the outcomes of clinical trials involving different ICBs. The aim is to inform clinicians and patients about the latest developments in ICBs therapy while underscoring the critical role of personalized medicine in addressing the diverse needs of patients. Ultimately, the research seeks to catalyze further exploration and innovation in melanoma treatment.
Insights
Advanced melanoma treatments like immune checkpoint blockades (ICBs) show promise but face challenges. Personalized medicine is crucial for improving outcomes in melanoma immunotherapy.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Melanoma is an aggressive skin cancer with increasing incidence and high mortality.
- Targeted therapies and immunotherapies, particularly immune checkpoint blockades (ICBs), are key treatments for metastatic melanoma.
- Current ICB treatments face limitations including toxicity, resistance, and varied patient responses.
Purpose of the Study:
- To review recent advancements in melanoma immunotherapy, focusing on immune checkpoint blockades (ICBs).
- To synthesize findings from research and clinical trials on ICBs in melanoma.
- To highlight the importance of personalized medicine for optimizing melanoma treatment.
Main Methods:
- Comprehensive literature review of melanoma immunotherapy.
- Analysis of clinical trial data for various immune checkpoint blockades (ICBs).
- Synthesis of current understanding of immune checkpoints in melanoma.
Main Results:
- Significant progress has been made in understanding melanoma immune checkpoints.
- Clinical trials demonstrate varying outcomes with different ICBs.
- Inter-patient heterogeneity necessitates tailored therapeutic strategies.
Conclusions:
- Immune checkpoint blockades (ICBs) are vital in advanced melanoma treatment.
- Addressing resistance, toxicity, and response heterogeneity is critical.
- Personalized medicine approaches are essential for advancing melanoma immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...